Barth T, Zeman F, Helbig H, Gamulescu M-A
Department of Ophthalmology, University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Centre for Clinical Studies (ZKS), University Medical Centre Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Int Ophthalmol. 2018 Jun;38(3):923-931. doi: 10.1007/s10792-017-0536-0. Epub 2017 Apr 19.
To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections.
Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed.
Eleven women and five men with a mean age of 35 years (SD 11, range 16-56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1-9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6-40 months). BCVA improved in eight eyes (mean Δ +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Δ -4.3 lines).
CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.
评估继发于点状内层脉络膜病变（PIC）的脉络膜新生血管（CNV）患者接受玻璃体内抗血管内皮生长因子（VEGF）注射的治疗效果。
回顾性评估16例诊断为继发于PIC的CNV患者的16只眼。
11名女性和5名男性，平均年龄35岁（标准差11，范围16 - 56岁），接受玻璃体内抗VEGF治疗PIC相关的CNV。每只眼平均注射3.5次（标准差2.7，范围1 - 9次）。13只眼接受贝伐单抗治疗，2只眼接受雷珠单抗治疗，1只眼同时接受两种药物治疗。平均随访15个月（标准差11，范围6 - 40个月）。8只眼的最佳矫正视力（BCVA）提高（平均提高2.8行），4只眼保持稳定，4只眼下降（平均下降4.3行）。
CNV的发生是PIC常见的并发症。玻璃体内抗VEGF治疗对于PIC相关的CNV似乎是安全有效的。
